US Stock MarketDetailed Quotes
VIGL Vigil Neuroscience
- 3.510
- +0.080+2.33%
Close Aug 23 16:00 ET
- 3.289
- -0.221-6.30%
Post 20:01 ET
139.16MMarket Cap-1663P/E (TTM)
3.580High3.350Low80.27KVolume3.460Open3.430Pre Close279.80KTurnover0.38%Turnover RatioLossP/E (Static)39.65MShares9.24052wk High1.63P/B73.68MFloat Cap2.47052wk Low--Dividend TTM20.99MShs Float18.270Historical High--Div YieldTTM6.71%Amplitude2.180Historical Low3.485Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Vigil Neuroscience Stock Forum
Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer’s Disease
Vigil Neuroscience (Nasdaq: VIGL) has announced promising interim data from its ongoing Phase 1 clinical trial of VG-3927, a potential once-daily oral therapy for Alzheimer's disease (AD).
The trial, which has enrolled 80 healthy volunteers, demonstrated a favorable safety and tolerabi...
Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference
-July 30 9AM EDT
Vigil Neuroscience (Nasdaq: VIGL) announced three presentations on its small molecule TREM2 agonist VG-3927at the 2024 Alzheimer's Association International Conference (AAIC) in Philadelphia. The presentations include:
1. An oral presentation on the characterization of VG-3927 for clinical development in...
Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP
Vigil Neuroscience (Nasdaq: VIGL) has updated its clinical development strategy for iluzanebart in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)following a Type C Meeting with the FDA.
The company will preserve the IGNITE dataset for a final analysis at 12 months, foregoing an interim anal...
But it barely hit even 10 dollars. why is it so? hmm
Vigil Neuroscience, a clinical-stage biotechnology firm, recently disclosed a $40 million investment from Sanofi, a prominent player in the biopharmaceutical industry. This investment is set at an as-converted price of $7.44 per share of common stock, which stands notably higher than the previous day’s c...
No comment yet